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No Xenotropic 
Murine Leukemia 
Virus–related Virus 
Detected in 
Fibromyalgia Patients 
To the Editor: Xenotropic mu-
rine leukemia virus–related virus 
(XMRV) is a recently described hu-
man retrovirus that has been associat-
ed with prostate cancer and chronic fa-
tigue syndrome (CFS) (1,2). XMRV is 
similar to a classic murine endogenous 
leukemia retrovirus, murine leukemia 
virus (MLV), which infects strains 
of mice that do not express the spe-
ciﬁ  c viral receptor. XMRV is geneti-
cally close to, although differentiable 
from, MLV. The ﬁ  rst evidence of its 
presence in humans was obtained by 
Urisman et al. in prostate cancer tis-
sue (1). In 2009, Lombardi et al. (2) 
found XMRV sequences and speciﬁ  c 
antibody responses in 67% of a large 
group of patients with CFS in North 
America. This association was notable 
because XMRV sequences were found 
in only 4% of healthy controls. These 
results have generated controversy 
because several independent studies, 
mainly in Europe (3–5) but also in 
North America (6), have been unable 
to detect XMRV sequences in patients 
with CFS. Furthermore, a recent re-
port from North America (7) appears 
to conﬁ  rm the initial results by Lom-
bardi et al. (2) in patients with CFS 
and expands the viral association to a 
wider variety of XMLV-related viruses 
that seem closer to polytropic mouse 
endogenous retroviruses.
Fibromyalgia is a multifactor 
condition characterized by wide-
spread pain and diffuse tenderness. 
Although trauma and stress can wors-
en or even precipitate development of 
the syndrome, infections with certain 
viruses, including hepatitis C virus 
and HIV, have been associated with 
development of ﬁ  bromyalgia  (8). 
Nevertheless,  ﬁ  bromyalgia  remains 
a disease of unknown etiology. Al-
though CFS is a distinct entity, fea-
tures shared by both diseases suggest 
that CFS and ﬁ  bromyalgia represent 
the same underlying condition (9). 
Additionally, because they are often 
accompanied by a noticeable mental 
health effect (9), the presence of a 
potential neurotropic retroviral agent 
in both diseases could explain these 
similarities. Therefore, we studied 
the presence of XMRV and poly-
tropic MLV–related retroviruses in a 
group of patients with ﬁ  bromyalgia.
During January 2010, blood 
samples were collected from 15 pa-
tients in whom ﬁ  bromyalgia had been 
previously diagnosed according to 
American College of Rheumatol-
ogy criteria (www.rheumatology.org/
practice/clinical/classiﬁ  cation/ﬁ  bro-
myalgia/1990_Criteria_for_Classiﬁ  -
cation_Fibro.pdf). Ten healthy blood 
donors served as controls. For XMRV 
screening, we used DNA extracted 
from 400 μL of whole blood collected 
in EDTA tubes by the QIAamp DNA 
Mini Kit (QIAGEN, Hilden, Germa-
ny). Nested PCR was done by using 
5 sets of primers corresponding to the 
gag (3) and env (2) regions of XMRV 
as described (2,3,7). The ﬁ  rst round of 
PCR was conducted by using 500 ng 
of genomic DNA, equivalent to 7.5 
× 104 nucleated blood cells, in a ﬁ  nal 
volume of 50 μL, by using the Expand 
High Fidelity PCR System (Roche 
Applied Science, Basel, Switzerland). 
A second round of PCR was conduct-
ed under the same conditions by using 
5 μL of the ﬁ  rst reaction product. De-
tails of the nested-PCR strategy were 
as follows: gag region was ampliﬁ  ed 
by outer primers 419F and 1154R (2) 
and 3 sets of inner primers: XMRV-
FI-441/XMRV-RI-566 (3), MLV-
GAG-I-F/MLV-GAG-I-R, and MLV-
NP116/MLV-NP117 (7). Nested PCR 
for env was performed by using outer 
primers 5922F and 6273R (2) and 2 
sets of inner primers: 5922F/6173R 
and 5942F/6159R (7). Primers for hu-
man β-globin were used as positive 
controls of human DNA ampliﬁ  cation 
(3). The full-length molecular viral 
clone VP62 (obtained through the 
National Institutes of Health AIDS 
Research and Reference Reagent Pro-
gram [Rockville, MD, USA] from 
R.H. Silverman and B. Dong) (10) 
was used as a positive XMRV con-
trol. All samples were examined on a 
2% agarose gel stained with ethidium 
bromide (Figure). The overall sensi-
tivity of the nested PCR procedure, 
estimated by spiking VP62 into nega-
tive samples, was 1–10 copies per 
sample.
Using highly sensitive PCR tools 
and a multiple set of primers to detect 
xenotropic and polytropic MLV–relat-
ed sequences, we found no evidence 
of MLV-related sequences in blood 
cells from ﬁ   bromyalgia patients or 
controls. Our results agree with those 
from studies of CFS cohorts in Europe 
and North America that also failed 
to conﬁ  rm XMRV in blood samples 
(3–6). Technical issues or geographic 
speciﬁ   cities probably could not ac-
count for such a difference; therefore, 
these negative results raise concerns 
about the role of XMRV in these 
syndromes. Nevertheless, with this 
relatively small population we can-
not absolutely exclude an association 
of XMRV or polytropic MLV–related 
viruses with ﬁ  bromyalgia. However, a 
proportion of ﬁ  bromyalgia cases with 
XMRV >22% would be unlikely (3/15 
cases, 95% conﬁ  dence interval 0–3), 
which is clearly insufﬁ   cient to sup-
port a signiﬁ  cant association between 
XMRV and ﬁ  bromyalgia.
Fibromyalgia does not appear to 
be associated with XMRV or poly-
tropic MLV–related viruses. The role 
of these new agents in human disease, 
and speciﬁ  cally in CFS, remains to be 
clearly conﬁ  rmed in multicenter and 
standardized studies.
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Clonal Spread of 
Streptococcus 
pyogenes emm44 
among Homeless 
Persons, Rennes, 
France
To the Editor: Streptococcus pyo-
genes, or group A streptococci (GAS), 
are human pathogens responsible for 
pharyngitis as well as skin and soft tis-
sue infections. Invasive GAS diseases, 
including bacteremia, cellulitis, and 
necrotizing fasciitis, are life-threaten-
ing, especially when associated with 
toxic shock syndrome. Several risk 
factors for GAS infections are known, 
such as diabetes, immunosuppression, 
drug use, and skin lesions (1,2).
In France in 2008, 12% of GAS 
strains were reported resistant to tetra-
cycline by the national reference center. 
Unexpected recognition of 8 tetracy-
cline-resistant GAS isolates in January 
and February 2009 at the 1,950-bed 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011  315 
Figure. Testing for xenotropic murine leukemia virus–related virus (XMRV) in patients with 
ﬁ  bromyalgia. Lanes 1 and 13, molecular weight marker ΦX174RF HaeIII; lanes 2–5, hBG 
for patients 1–4 (primers: hBG-FI-170/hBG-RI-273 (103 bp); lanes 6–12, positive control 
(pcDNA3.1-XMRV-Vp62) 1,000 copies (lanes 6 and 10) and 100 copies (lanes 7–9 and 
11–12); lane 6, primers gag 419F/1154R (735 bp); lane 7, primers gag MLV-GAG-I-F/MLV-
GAG-I-R (413 bp); lane 8, primers gag MLV-NP116/MLV-NP117 (380 bp); lane 9, primers 
gag XMRV-FI-441/XMRV-RI-566 (125 bp); lane 10, primers env 5922F/6273R (351 bp); 
lane 11, primers env 5922F/6173R (252 bp); lane 12, primers env 5942F/6159R (218 bp).